DEF 14A: Biomerica Seeks Stockholder Approval for Reverse Stock Split, Stock Incentive Plan, and More at Upcoming Annual Meeting

Biomerica, Inc. is holding its annual meeting on December 13, 2024, seeking stockholder approval for several key proposals, including a reverse stock split, a new stock incentive plan, and amendments to the company's certificate of incorporation.

Summary

• Biomerica, Inc. will hold its annual meeting of stockholders on December 13, 2024, at its Irvine, California headquarters.
• Stockholders will vote on several proposals, including the election of five directors, an advisory vote on executive compensation, and the ratification of Haskell & White LLP as the independent accounting firm for the fiscal year ending May 31, 2025.
• A key proposal is the approval of the 2024 Stock Incentive Plan, which would authorize the issuance of 1,600,000 shares of restricted stock or stock options.
• Stockholders will also vote on an amendment to the company's certificate of incorporation to allow the board to effect a reverse stock split of the common stock, with a ratio between 1-for-3 and 1-for-15.
• Another proposed amendment would authorize the board to increase the number of authorized shares of common stock.
• The record date for determining stockholders eligible to vote at the meeting was October 16, 2024.
• As of September 30, 2024, there were 16,821,646 shares of common stock outstanding and entitled to vote.
• The board recommends voting in favor of all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting necessary information for the annual meeting. The need for a reverse stock split introduces some concern, but the overall sentiment is balanced.

Positives

• The proposed reverse stock split aims to maintain the company's Nasdaq listing and potentially attract a broader range of investors.
• The 2024 Stock Incentive Plan is intended to attract and retain qualified directors, managers, and personnel.
• The proposed increase in authorized shares provides flexibility for future capital raising and strategic transactions.

Negatives

• The company received a delisting notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share.
• Reverse stock splits can have a negative perception among some investors.
• Future issuances of common stock may dilute the ownership interest of current stockholders.

Risks

• If stockholders do not approve the reverse stock split, the company may be delisted from the Nasdaq Capital Market.
• Even if the reverse stock split is approved, the company may still be subject to delisting if the bid price of the common stock fails to stay above $1.00 for the required 10 trading day period.
• The market price of the common stock may not increase as a result of the reverse stock split.
• An increase in the number of authorized shares of common stock could be used to deter a potential takeover of the company.

Future Outlook

The company aims to maintain its Nasdaq listing, attract investors, and raise capital to execute its business plan and finance strategic objectives.

Management Comments

• The Board believes that the proposed increase in the number of authorized shares of Common Stock will benefit the Company by improving our flexibility to promptly and appropriately use its Common Stock for business and financial purposes in the future.
• The Board believes the Plan will enhance the Company's ability to recruit and maintain qualified directors, managers, and personnel by including stock options as part of compensation packages.

Industry Context

The document highlights the importance of maintaining a Nasdaq listing for Biomerica, which is a common concern for publicly traded companies, especially smaller ones. The reverse stock split is a tool often used by companies facing delisting to regain compliance with minimum share price requirements. The document also mentions Evolus, Inc., a publicly traded life sciences company, providing a benchmark for Biomerica's board members' experience.

Comparison to Industry Standards

• The document mentions CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where Allen Barbieri served as a board member, indicating experience in corporate governance and finance.
• The document references Evolus, Inc. (NASDAQ: EOLS), a publicly traded life sciences company, where David Moatazedi serves as CEO, providing a benchmark for Biomerica's board members' experience in the life sciences industry.
• The document mentions Renalytix, plc(NASDAQ: RNLX), an artificial intelligence-enable in vitro diagnostics company, where Catherine Coste serves as an Independent Director, providing a benchmark for Biomerica's board members' experience in the diagnostics industry.

Management Changes

Stakeholder Impact

• The reverse stock split and potential delisting could negatively impact shareholders.
• The stock incentive plan aims to benefit employees and directors by aligning their interests with shareholder value.
• The increase in authorized shares could provide the company with more flexibility to raise capital and pursue strategic opportunities, potentially benefiting all stakeholders.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on December 13, 2024.
• The Board will determine whether to proceed with the reverse stock split and, if so, the specific ratio.
• The Board will consider whether to implement the Authorized Share Increase.

Key Dates

Keywords

reverse stock split, stock incentive plan, annual meeting, proxy statement, authorized shares, director election, executive compensation, Biomerica, BMRA